Gilead Subsidiary, Kite, And HiFiBiO Therapeutics Announce Research Collaboration o Develop Technology For The Potential Discovery Of Neoantigen-Reactive T Cell Receptors (TCRs) Cancer Treatment; HiFiBio Will Receive $10M Upfront Payment
Benzinga_Newsdesk